Bulk Pharmaceutical API Sources for NAPHCON FORTE

Bulk Pharmaceutical API Sources for NAPHCON FORTE

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		N5504_SIGMA
TCI (Tokyo Chemical Industry)		N0542
Molport		MolPort-002-904-680
Amadis Chemical		A830484
TimTec		SBB017549
TimTec		ST50319852

Naphcon Forte API Sourcing Landscape

Last updated: February 19, 2026

This report analyzes the current landscape of bulk Active Pharmaceutical Ingredient (API) sources for Naphcon Forte, a ophthalmic solution containing naphazoline hydrochloride. The analysis focuses on identifying key API manufacturers, regulatory compliance, and market accessibility for procurement professionals.

What is Naphcon Forte and its API?

Naphcon Forte is an ophthalmic vasoconstrictor used to relieve redness of the eye due to minor eye irritations. The active pharmaceutical ingredient (API) is naphazoline hydrochloride. Naphazoline hydrochloride is a sympathomimetic amine that acts as an alpha-adrenergic agonist, causing constriction of the blood vessels in the eye. This reduces conjunctival hyperemia, or redness, associated with allergies, smoke, or fatigue [1].

The chemical structure of naphazoline hydrochloride is 2-(1-naphthylmethyl)-2-imidazoline hydrochloride. Its molecular formula is C14H14N2•HCl, and its molecular weight is 246.74 g/mol [2]. The API is typically supplied as a white or almost white crystalline powder, sparingly soluble in water and soluble in ethanol [3].

Key Manufacturers of Naphazoline Hydrochloride API

The production of naphazoline hydrochloride API is concentrated among a limited number of global manufacturers. These entities often serve both the generic pharmaceutical industry and custom synthesis markets. Key players identified through patent filings, regulatory submissions, and industry databases include:

• Alkem Laboratories Ltd. (India): A large Indian pharmaceutical company with significant API manufacturing capabilities. Alkem is known to produce a range of ophthalmic APIs.
• Divi's Laboratories Limited (India): A major Indian API manufacturer recognized for its large-scale production and robust regulatory compliance, particularly with US FDA and EDQM standards.
• Laurus Labs Limited (India): Another prominent Indian API producer with a growing portfolio of specialty APIs. Laurus Labs has a strong focus on quality and regulatory affairs.
• Shandong Xinhua Pharmaceutical Co., Ltd. (China): A significant Chinese pharmaceutical manufacturer with a long history in API production. They supply a broad spectrum of pharmaceutical ingredients globally.
• Zhejiang NHU Company Ltd. (China): A large chemical and pharmaceutical enterprise in China, involved in the production of various APIs and intermediates.

Table 1: Selected Naphazoline Hydrochloride API Manufacturers and Key Characteristics

Manufacturer Name	Country of Origin	Primary Regulatory Approvals (Examples)	Key Strengths (Reported)
Alkem Laboratories Ltd.	India	US FDA, EDQM	Scale, diverse product portfolio
Divi's Laboratories Limited	India	US FDA, EDQM, PMDA	Large-scale manufacturing, strong quality systems
Laurus Labs Limited	India	US FDA, EDQM	Specialty API focus, robust R&D
Shandong Xinhua Pharmaceutical Co., Ltd.	China	US FDA, EDQM	Established production capacity, global reach
Zhejiang NHU Company Ltd.	China	US FDA, EDQM	Integrated manufacturing, competitive pricing potential

Note: Specific product availability and regulatory status may vary and require direct inquiry.

Regulatory Compliance and Quality Standards

Procurement of naphazoline hydrochloride API for Naphcon Forte requires adherence to stringent regulatory standards to ensure product safety and efficacy. Key regulatory bodies and their requirements are critical for API suppliers:

• U.S. Food and Drug Administration (FDA): Manufacturers supplying to the U.S. market must comply with Current Good Manufacturing Practices (cGMP). FDA inspections and Drug Master File (DMF) submissions are standard requirements. A US DMF filed for naphazoline hydrochloride allows drug product manufacturers to reference the API information in their Abbreviated New Drug Applications (ANDAs) or New Drug Applications (NDAs).
• European Directorate for the Quality of Medicines & HealthCare (EDQM): For the European market, Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) are often preferred. CEPs demonstrate that the API complies with the relevant European Pharmacopoeia monograph, facilitating the Marketing Authorisation Application (MAA) process in EU member states.
• Other National Regulatory Agencies: Compliance with regulations from agencies such as Japan's Pharmaceuticals and Medical Devices Agency (PMDA), India's Central Drugs Standard Control Organisation (CDSCO), and China's National Medical Products Administration (NMPA) is essential for market-specific approvals.
• Pharmacopoeial Standards: API must meet the specifications outlined in relevant pharmacopoeias, including the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). These monographs detail purity, identity, and assay requirements.

Table 2: Key Regulatory Considerations for Naphazoline Hydrochloride API

Regulatory Aspect	Description	Impact on Procurement
cGMP Compliance	Adherence to FDA's Current Good Manufacturing Practices for all manufacturing, processing, packing, and holding of APIs.	Ensures quality, consistency, and traceability. Non-compliance can lead to import alerts and market exclusion.
Drug Master Files (DMFs)	Confidential detailed information submitted to regulatory authorities about facilities, processes, and controls used in API manufacturing.	Facilitates regulatory review for drug product applications (ANDAs, NDAs). Requires active DMF status.
Certificates of Suitability (CEPs)	EDQM issued certificates demonstrating compliance with European Pharmacopoeia monographs.	Streamlines MAA process in EU. Demonstrates API quality meets European standards.
Pharmacopoeial Compliance	Meeting specifications outlined in USP, Ph. Eur., JP, or other relevant national pharmacopoeias.	Essential for API quality and acceptance in finished drug products.
Impurity Profiling	Comprehensive identification and control of process-related impurities and degradation products.	Critical for safety and regulatory approval. ICH Q3A guidelines are typically followed.
Stability Studies	Data demonstrating API stability under various storage conditions.	Determines shelf-life and storage recommendations. Essential for DMF and regulatory submissions.

Patent Landscape and Exclusivity

The patent landscape for naphazoline hydrochloride itself is mature, with primary patents on the compound long expired. However, patents related to novel synthetic routes, specific polymorphic forms, purification methods, or new formulations (e.g., controlled-release ophthalmic solutions) can still impact market dynamics.

• Composition of Matter Patents: Original patents covering naphazoline hydrochloride have expired, allowing for generic manufacturing.
• Process Patents: While less common for well-established APIs, new, more efficient, or environmentally friendly synthetic routes might be patented. These could offer competitive advantages in terms of cost or purity.
• Polymorph Patents: Different crystalline forms (polymorphs) of an API can affect its stability, solubility, and bioavailability. Patents on specific, therapeutically advantageous polymorphs could exist.
• Formulation Patents: Patents related to the final Naphcon Forte product, such as novel excipients, delivery systems, or preservative blends that enhance stability or efficacy, are relevant. However, the API itself is generally off-patent.

A thorough patent search is recommended to identify any active patents that might influence the sourcing strategy, particularly concerning novel manufacturing processes or specific API characteristics claimed in recent filings.

Market Dynamics and Procurement Considerations

The global supply of naphazoline hydrochloride API is largely influenced by the capacity and regulatory standing of manufacturers in India and China.

• Cost Competitiveness: Manufacturers in India and China generally offer competitive pricing due to lower manufacturing overheads and economies of scale.
• Supply Chain Reliability: Diversifying API suppliers is crucial to mitigate risks associated with single-source dependency, geopolitical instability, or unforeseen manufacturing disruptions.
• Quality Assurance: Rigorous vendor qualification processes, including on-site audits, review of quality agreements, and testing of incoming API batches, are paramount.
• Lead Times: Standard lead times for bulk API can range from 8 to 16 weeks, depending on the manufacturer's production schedule and inventory levels. Expedited orders may incur additional costs.
• Regulatory Scrutiny: Increased regulatory oversight by global agencies means that API suppliers must maintain impeccable compliance records. Any regulatory action against a supplier can halt the supply of their API.

Table 3: Procurement Considerations for Naphazoline Hydrochloride API

Consideration	Detail
Supplier Qualification	Conduct due diligence on potential API manufacturers, including review of regulatory filings (DMFs, CEPs), audit reports, and quality agreements.
Quality Agreements	Establish comprehensive quality agreements detailing responsibilities for quality control, change management, and regulatory compliance.
Secondary Sourcing	Identify and qualify at least one alternative supplier to ensure supply chain continuity.
Forecasting	Provide accurate demand forecasts to API manufacturers to ensure adequate production planning and inventory management.
Contractual Terms	Negotiate clear terms regarding pricing, payment, delivery schedules, intellectual property, and product specifications.
Impurity Control	Ensure the API manufacturer has robust impurity control strategies in place and provides detailed Certificates of Analysis (CoAs) for each batch.
Change Control	Implement a strict change control process to manage any modifications to the API manufacturing process, specifications, or packaging.

Conclusion

The sourcing of naphazoline hydrochloride API for Naphcon Forte is primarily driven by manufacturers in India and China, who offer competitive pricing and possess significant production capacity. Key considerations for procurement professionals include ensuring robust regulatory compliance (US FDA, EDQM), validating manufacturing processes, and maintaining strong supplier relationships. While the compound itself is off-patent, vigilance regarding process and formulation patents is advised. Diversification of suppliers and rigorous quality assurance protocols are essential for ensuring a reliable and compliant supply chain.

Key Takeaways

• Primary API manufacturers for naphazoline hydrochloride are located in India and China.
• Regulatory compliance, particularly with US FDA and EDQM, is critical for market access.
• Drug Master Files (DMFs) and Certificates of Suitability (CEPs) are essential regulatory documents.
• A mature patent landscape for naphazoline hydrochloride allows for generic API production.
• Diversified sourcing and rigorous quality assurance are vital for supply chain reliability.

Frequently Asked Questions

1. What is the typical purity requirement for naphazoline hydrochloride API used in ophthalmic preparations? Naphazoline hydrochloride API for ophthalmic use typically requires a purity of not less than 98.0% and not more than 101.0% on the dried basis, as per USP monograph specifications. Specific impurity limits, including related substances and residual solvents, are also critical.

2. Are there any known issues with API supply chain disruptions for naphazoline hydrochloride? As with many APIs, supply chain disruptions can occur due to raw material shortages, manufacturing issues, or regulatory actions against manufacturers. Diversifying suppliers and maintaining buffer stock can mitigate these risks.

3. What is the significance of the polymorph of naphazoline hydrochloride API? Different polymorphic forms of an API can influence its solubility, stability, and dissolution rate, which in turn can affect the drug product's performance. While the primary naphazoline hydrochloride patents have expired, specific patents on therapeutically advantageous polymorphs could exist and impact sourcing.

4. How do I verify the cGMP compliance of an API manufacturer? Verification involves reviewing the manufacturer's site inspection reports from regulatory agencies (e.g., FDA inspection reports), requesting a copy of their FDA registration, reviewing their quality management system documentation, and potentially conducting an on-site audit.

5. What is the typical shelf life of naphazoline hydrochloride API? The shelf life of naphazoline hydrochloride API is typically determined by stability studies conducted by the manufacturer. It is generally expected to be between 2 to 5 years when stored under recommended conditions, as detailed in their stability data and product specifications.

Citations

[1] National Institutes of Health. (n.d.). Naphazoline. MedlinePlus. Retrieved from https://medlineplus.gov/druginfo/meds/a682313.html [2] PubChem. (n.d.). Naphazoline hydrochloride. National Center for Biotechnology Information. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Naphazoline-hydrochloride [3] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Monograph 0095: Naphazoline Hydrochloride. European Pharmacopoeia.